Application of 3D Fast Spin-Echo T1 Black-Blood Imaging in the Diagnosis and Prognostic Prediction of Patients with Leptomeningeal Carcinomatosis

References

1. 1.↵
   2. Bruna J,
   3. González L,
   4. Miró J, et al

   ; Neuro-Oncology Unit of the Institute of Biomedical Investigation of Bellvitge. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009;115:381–89 doi:10.1002/cncr.24041 pmid:19109820

   CrossRefPubMed
2. 2.↵
   2. Chamberlain MC

   . Neoplastic meningitis. Neurologist 2006;12:179–87 doi:10.1097/01.nrl.0000219732.33321.cc pmid:16832237

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Park JH,
   3. Kim YJ,
   4. Lee JO, et al

   . Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012;76:387–92 doi:10.1016/j.lungcan.2011.11.022 pmid:22186628

   CrossRefPubMed
4. 4.↵
   2. Nakagawa H,
   3. Murasawa A,
   4. Kubo S, et al

   . Diagnosis and treatment of patients with meningeal carcinomatosis. J Neurooncol 1992;13:81–89 pmid:1613540

   PubMed
5. 5.↵
   2. Shapiro WR,
   3. Johanson CE,
   4. Boogerd W

   . Treatment modalities for leptomeningeal metastases. Semin Oncol 2008;36:S46–54 pmid:1966060683

   PubMed
6. 6.↵
   2. Kaplan JG,
   3. DeSouza TG,
   4. Farkash A, et al

   . Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225–29 doi:10.1007/BF02341153 pmid:2086737

   CrossRefPubMed
7. 7.↵
   2. Taillibert S,
   3. Laigle-Donadey F,
   4. Chodkiewicz C, et al

   . Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 2005;75:85–99 doi:10.1007/s11060-004-8101-x pmid:16215819

   CrossRefPubMed
8. 8.↵
   2. Wasserstrom WR,
   3. Glass JP,
   4. Posner JB

   . Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759–72 pmid:6895713

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Freilich RJ,
   3. Krol G,
   4. DeAngelis LM

   . Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51–57 doi:10.1002/ana.410380111 pmid:7611725

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Clarke JL,
    3. Perez HR,
    4. Jacks LM, et al

    . Leptomeningeal metastases in the MRI era. Neurology 2010;74:1449–54 doi:10.1212/WNL.0b013e3181dc1a69 pmid:20439847

    Abstract/FREE Full Text
11. 11.↵
    2. Brant-Zawadzki M,
    3. Gillan GD,
    4. Nitz WR

    . MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence—initial experience in the brain. Radiology 1992;182:769–75 doi:10.1148/radiology.182.3.1535892 pmid:1535892

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Qiao Y,
    3. Steinman DA,
    4. Qin Q, et al

    . Intracranial arterial wall imaging using three-dimensional high isotropic resolution black blood MRI at 3.0 Tesla. J Magn Reson Imaging 2011;34:22–30 doi:10.1002/jmri.22592 pmid:21698704

    CrossRefPubMed
13. 13.↵
    2. Kato Y,
    3. Higano S,
    4. Tamura H, et al

    . Usefulness of contrast-enhanced T1-weighted sampling perfection with application-optimized contrasts by using different flip angle evolutions in detection of small brain metastasis at 3T MR imaging: comparison with magnetization-prepared rapid acquisition of gradient echo imaging. AJNR Am J Neuroradiol 2009;30:923–29 doi:10.3174/ajnr.A1506 pmid:19213825

    Abstract/FREE Full Text
14. 14.↵
    2. Park J,
    3. Kim EY

    . Contrast-enhanced, three-dimensional, whole-brain, black-blood imaging: application to small brain metastases. Magn Reson Med 2010;63:553–61 doi:10.1002/mrm.22261 pmid:20187162

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Singh SK,
    3. Leeds NE,
    4. Ginsberg LE

    . MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol 2002;23:817–21 pmid:12006284

    Abstract/FREE Full Text
16. 16.↵
    2. Hyun JW,
    3. Jeong IH,
    4. Joung A, et al

    . Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 2016;56:107–14 doi:10.1016/j.ejca.2015.12.021 pmid:26841095

    CrossRefPubMed
17. 17.↵
    2. Kak M,
    3. Nanda R,
    4. Ramsdale EE, et al

    . Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities. J Clin Neurosci 2015;22:632–37 doi:10.1016/j.jocn.2014.10.022 pmid:25677875

    CrossRefPubMed
18. 18.↵
    2. Li YS,
    3. Jiang BY,
    4. Yang JJ, et al

    . Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol 2016;11:1962–69 doi:10.1016/j.jtho.2016.06.029 pmid:27539328

    CrossRefPubMed
19. 19.↵
    2. An YJ,
    3. Cho HR,
    4. Kim TM, et al

    . An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. Int J Cancer 2015;136:162–71 doi:10.1002/ijc.28949 pmid:24798643

    CrossRefPubMed
20. 20.↵
    2. Mack F,
    3. Baumert B,
    4. Schäfer N, et al

    . Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev 2016;43:83–91 doi:10.1016/j.ctrv.2015.12.004 pmid:26827696

    CrossRefPubMed
21. 21.↵
    2. Contal C,
    3. O'Quigley J

    . An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational Statistics & Data Analysis 1999;30:253–70

    CrossRef
22. 22.↵
    2. Davis P,
    3. Friedman N,
    4. Fry S, et al

    . Leptomeningeal metastasis: MR imaging. Radiology 1987;163:449–54 doi:10.1148/radiology.163.2.3562825 pmid:3562825

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Chamberlain MC,
    3. Sandy AD,
    4. Press GA

    . Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990;40:435–38 doi:10.1212/WNL.40.3 Part 1.435 pmid:2314584

    Abstract/FREE Full Text
24. 24.↵
    2. Singh SK,
    3. Agris JM,
    4. Leeds NE, et al

    . Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging. Radiology 2000;217:50–53 doi:10.1148/radiology.217.1.r00oc3550 pmid:11012422

    CrossRefPubMed
25. 25.↵
    2. Mugler JP 3rd.,
    3. Brookeman JR

    . Theoretical analysis of gadopentetate dimeglumine enhancement in T1-weighted imaging of the brain: comparison of two-dimensional spin-echo and three-dimensional gradient-echo sequences. J Magn Reson Imaging 1993;3:761–69 doi:10.1002/jmri.1880030512 pmid:8400563

    CrossRefPubMed
26. 26.↵
    2. Gil B,
    3. Hwang EJ,
    4. Lee S, et al

    . Detection of leptomeningeal metastasis by contrast-enhanced 3D T1-SPACE: comparison with 2D FLAIR and contrast-enhanced 2D T1-weighted images. PLoS One 2016;11:e0163081 doi:10.1371/journal.pone.0163081 pmid:27695096

    CrossRefPubMed
27. 27.↵
    2. Åkeson P,
    3. Nordström CH,
    4. Holtås S

    . Time-dependency in brain lesion enhancement with gadodiamide injection. Acta Radiol 1997;38:19–24 pmid:9059396

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Schörner W,
    3. Laniado M,
    4. Niendorf H, et al

    . Time-dependent changes in image contrast in brain tumors after gadolinium-DTPA. AJNR Am J Neuroradiol 1986;7:1013–20 pmid:3098065

    Abstract/FREE Full Text
29. 29.↵
    2. Jeon JY,
    3. Choi JW,
    4. Roh HG, et al

    . Effect of imaging time in the magnetic resonance detection of intracerebral metastases using single dose gadobutrol. Korean J Radiol 2014;15:145–50 doi:10.3348/kjr.2014.15.1.145 pmid:24497805

    CrossRefPubMed